Stephen H. Friend
Research Subjects
Stephen H. Friend has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Hongyue Dai
Rosetta Inpharmatics LLC, Seattle, Washington 98109
2 shared publicationsAlan Sachs
Rosetta Inpharmatics LLC, (A wholly owned subsidiary of Merck & Co. Inc.) Seattle, Washington
1 shared publication- Bernard M. Fine
Department of Physics and Center for Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
1 shared publication Dennis Schmatz
Dennis Schmatz and Stephen Friend are at Merck & Company, 770 Sumneytown Pike, West Point, Pennsylvania 19486, USA
1 shared publication- Eric E. Schadt
Genetics Dept., Rosetta Inpharmatics, LLC, wholly owned subsidiary of Merck & Co., Inc., 401 Terry Avenue North, Seattle Washington, 98109, USA
1 shared publication John Lamb
Rosetta Inpharmatics LLC, (A wholly owned subsidiary of Merck & Co. Inc.) Seattle, Washington
1 shared publication
Latest Publications
- Open Access
- 30 November 2006
- Published by Elsevier in Cancer Cell
- Vol. 10 (5) , 349-351
Accelerating drug discovery: Open source cancer cell biology?
- 30 November 2006
- Published by Elsevier in Cancer Cell
- Vol. 10 (5) , 349-351
Open AccessAccelerating drug discovery: Open source cancer cell biology?
- 26 May 2006
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 312 (5777) , 1165-1168
Cancer Biomarkers—An Invitation to the Table
The allure of the emerging genomic technologies in cancer is their ability to generate new biomarkers that predict how individual cancer patients will respond to various treatments. However, productive implementation of cancer biomarkers into patient care will require fundamental changes in how we consider approvals for cancer indications and how we track patient responses. Here we briefly describe ongoing efforts to identify and to validate cancer biomarkers, discuss the technological hurdles that lie ahead, and then focus on the more pressing political and cultural issues that, if left unheeded, could derail many of the anticipated benefits of biomarker research.
- 26 May 2006
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 312 (5777) , 1165-1168
Cancer Biomarkers—An Invitation to the Table
The allure of the emerging genomic technologies in cancer is their ability to generate new biomarkers that predict how individual cancer patients will respond to various treatments. However, productive implementation of cancer biomarkers into patient care will require fundamental changes in how we consider approvals for cancer indications and how we track patient responses. Here we briefly describe ongoing efforts to identify and to validate cancer biomarkers, discuss the technological hurdles that lie ahead, and then focus on the more pressing political and cultural issues that, if left unheeded, could derail many of the anticipated benefits of biomarker research.
- 1 April 2006
- Published by Springer Nature in Nature Genetics
- Vol. 38 (4) , 405-406
A simple recipe for drug interaction networks earns its stars.
- 1 April 2006
- Published by Springer Nature in Nature Genetics
- Vol. 38 (4) , 405-406
A simple recipe for drug interaction networks earns its stars.
- Open Access
- 15 May 2005
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (10) , 4059-4066
A Cell Proliferation Signature Is a Marker of Extremely Poor Outcome in a Subpopulation of Breast Cancer Patients
Breast cancer comprises a group of distinct subtypes that despite having similar histologic appearances, have very different metastatic potentials. Being able to identify the biological driving force, even for a subset of patients, is crucially important given the large population of women diagnosed with breast cancer. Here, we show that within a subset of patients characterized by relatively high estrogen receptor expression for their age, the occurrence of metastases is strongly predicted by a homogeneous gene expression pattern almost entirely consisting of cell cycle genes (5-year odds ratio of metastasis, 24.0; 95% confidence interval, 6.0-95.5). Overexpression of this set of genes is clearly associated with an extremely poor outcome, with the 10-year metastasis-free probability being only 24% for the poor group, compared with 85% for the good group. In contrast, this gene expression pattern is much less correlated with the outcome in other patient subpopulations. The methods described here also illustrate the value of combining clinical variables, biological insight, and machine-learning to dissect biological complexity. Our work presented here may contribute a crucial step towards rational design of personalized treatment.
- 15 May 2005
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (10) , 4059-4066
Open AccessA Cell Proliferation Signature Is a Marker of Extremely Poor Outcome in a Subpopulation of Breast Cancer Patients
Breast cancer comprises a group of distinct subtypes that despite having similar histologic appearances, have very different metastatic potentials. Being able to identify the biological driving force, even for a subset of patients, is crucially important given the large population of women diagnosed with breast cancer. Here, we show that within a subset of patients characterized by relatively high estrogen receptor expression for their age, the occurrence of metastases is strongly predicted by a homogeneous gene expression pattern almost entirely consisting of cell cycle genes (5-year odds ratio of metastasis, 24.0; 95% confidence interval, 6.0-95.5). Overexpression of this set of genes is clearly associated with an extremely poor outcome, with the 10-year metastasis-free probability being only 24% for the poor group, compared with 85% for the good group. In contrast, this gene expression pattern is much less correlated with the outcome in other patient subpopulations. The methods described here also illustrate the value of combining clinical variables, biological insight, and machine-learning to dissect biological complexity. Our work presented here may contribute a crucial step towards rational design of personalized treatment.
- 8 October 2003
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 38 (4) , 326-328
Alfred Knudson: The importance of a visionary who enables scientists
- 8 October 2003
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 38 (4) , 326-328
Alfred Knudson: The importance of a visionary who enables scientists
- 1 April 2003
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 31 (2) , 437-443
A new paradigm for drug discovery: integrating clinical, genetic, genomic and molecular phenotype data to identify drug targets
Application of statistical genetics approaches to variations in mRNA transcript abundances in segregating populations can be used to identify genes and pathways associated with common human diseases. The combination of this genetic information with gene expression and clinical trait data can also be used to identify subtypes of a disease and the genetic loci specific to each subtype. Here we highlight results from some of our recent work in this area and further explore the many possibilities that exist in employing a more comprehensive genetics and functional genomics approach to the functional annotation of genomes, and in applying such methods to the validation of targets for complex traits in the drug discovery process.
- 1 April 2003
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 31 (2) , 437-443
A new paradigm for drug discovery: integrating clinical, genetic, genomic and molecular phenotype data to identify drug targets
Application of statistical genetics approaches to variations in mRNA transcript abundances in segregating populations can be used to identify genes and pathways associated with common human diseases. The combination of this genetic information with gene expression and clinical trait data can also be used to identify subtypes of a disease and the genetic loci specific to each subtype. Here we highlight results from some of our recent work in this area and further explore the many possibilities that exist in employing a more comprehensive genetics and functional genomics approach to the functional annotation of genomes, and in applying such methods to the validation of targets for complex traits in the drug discovery process.